Glenmede Trust Co. NA grew its position in Zoetis Inc (NYSE:ZTS) by 102.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,038 shares of the company’s stock after purchasing an additional 22,770 shares during the period. Glenmede Trust Co. NA’s holdings in Zoetis were worth $3,837,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in ZTS. Polen Capital Management LLC increased its holdings in shares of Zoetis by 125.3% in the first quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company’s stock valued at $746,883,000 after purchasing an additional 4,974,081 shares during the period. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Zoetis by 319.9% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock valued at $231,187,000 after purchasing an additional 2,109,036 shares during the period. Banque Pictet & Cie SA increased its holdings in shares of Zoetis by 5,516.1% in the second quarter. Banque Pictet & Cie SA now owns 1,679,617 shares of the company’s stock valued at $143,087,000 after purchasing an additional 1,649,710 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Zoetis by 22.3% in the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock valued at $460,890,000 after purchasing an additional 985,586 shares during the period. Finally, Bank of Montreal Can increased its holdings in shares of Zoetis by 190.7% in the second quarter. Bank of Montreal Can now owns 1,327,357 shares of the company’s stock valued at $113,078,000 after purchasing an additional 870,807 shares during the period. 89.71% of the stock is currently owned by institutional investors and hedge funds.

ZTS has been the topic of a number of research reports. Cantor Fitzgerald set a $98.00 price objective on Zoetis and gave the company a “buy” rating in a report on Thursday, August 2nd. Stifel Nicolaus raised their target price on Zoetis from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Morgan Stanley raised their target price on Zoetis from $87.00 to $92.00 and gave the stock a “hold” rating in a report on Friday, August 3rd. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a report on Monday, September 10th. Finally, Jefferies Financial Group set a $96.00 target price on Zoetis and gave the stock a “buy” rating in a report on Friday, July 13th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Zoetis has an average rating of “Buy” and a consensus target price of $91.73.

Zoetis stock opened at $90.26 on Wednesday. The stock has a market cap of $43.28 billion, a P/E ratio of 37.61, a P/E/G ratio of 1.70 and a beta of 1.02. Zoetis Inc has a 52 week low of $62.79 and a 52 week high of $93.67. The company has a current ratio of 4.38, a quick ratio of 2.92 and a debt-to-equity ratio of 2.50.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.71 by $0.06. The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. Zoetis’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $0.53 earnings per share. research analysts anticipate that Zoetis Inc will post 3.07 earnings per share for the current fiscal year.

In other Zoetis news, CFO Glenn David sold 16,385 shares of the stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $92.20, for a total transaction of $1,510,697.00. Following the transaction, the chief financial officer now owns 29,234 shares in the company, valued at $2,695,374.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $84.76, for a total value of $169,520.00. Following the transaction, the insider now owns 22,023 shares in the company, valued at approximately $1,866,669.48. The disclosure for this sale can be found here. Insiders have sold 213,467 shares of company stock worth $19,488,185 in the last quarter. 0.35% of the stock is currently owned by company insiders.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.